Prescription Drug Affordability Board (PDAB)

PDAB wants to hear from Oregonians about drug costs

The Oregon Prescription Drug Affordability Board (PDAB) is seeking input from patients, caregivers, and others about the cost of prescription medications. The board invites patients, caregivers, advocacy groups, medical professionals, manufacturers, safety net clinics, pharmacy benefit managers, and health plan insurers to submit a feedback form about the prescription drugs currently under board review: Jardiance; Mounjaro; Ozempic; Humulin R U-500; Keytruda; Verzenio; Xeljanz; Ocrevus; Skyrizi; Tremfya; and Xolair. If any of these medications have affected your health, finances, or communities, please share your experiences with the board. Your feedback will help inform PDAB’s review process.

Click on the link below to select the applicable form, complete the questions, and submit the form. Thank you in advance for your participation.

Submit a feedback form about a prescription drug!

The next PDAB meeting is:

Wednesday, June 17, 2026
8 A.M. Pacific Time

Oregon PDAB seeks applicants to fill future board vacancies; apply by June 5

The Oregon Prescription Drug Affordability Board is seeking applicants to fill two future vacancies. Members of the board must be Oregon residents with expertise in health care economics and clinical medicine. PDAB consists of eight members appointed by the governor and confirmed by the Oregon State Senate. Members serve four-year terms and may seek reappointment. The time commitment is approximately 15 hours per month, including virtual board meetings held on the third Wednesday of the month. We anticipate appointing new board members in fall 2026, with terms beginning in January 2027.

About the PDAB

The Oregon Prescription Drug Affordability Board is established in the Department of Consumer and Business Services under ORS 646A.693 to protect residents of Oregon, state and local governments, commercial health plans, health care providers, pharmacies licensed in Oregon and others within the health care system in this state from the high costs of prescription drugs. To learn more about the board’s work, see the FAQ page.